Age of onset for disease is an important factor affecting clinical outcomes across the life span in patients receiving disease-modifying therapy (DMT) for multiple sclerosis (MS), according to a study published recently in the European Journal of Neurology.

Viktor von Wyl, Ph.D., from the University of Zurich, and colleagues used data from a database of Swiss health insurers to identify 9,705 MS patients (including 236 pediatric-onset patients) taking DMT for at least one year. Associations between age at disease onset and clinical outcomes were evaluated.

Read the full article at